Annual Meeting 2015: Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

Annual Meeting 2015: Nivolumab Extends Survival for Patients With the Most Common Lung Cancer

EMJ

5 years
919 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC). Among patients with advanced disease that worsened after receiving platinum-based chemotherapy, those treated with nivolumab lived on average three months longer than those treated with docetaxel chemotherapy. Presented at ASCO 2015, Chicago, IL by Professor Luis Paz-Ares, MD, PhD, Hospital Universitario 12 de Octubre, Madrid, Spain European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay